Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.75 |
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | PHGDH | O43175 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | NSD2 | O96028 | 1/20 | 0.57 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.57 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2376773 | 0.88 | PKM (0.75) | PKMHPGDKMT2AGLAPHGDH | |
| SCHEMBL20516444 | 0.84 | HPGD (0.71) | PKMHPGDKMT2AGLAL3MBTL1 | |
| SCHEMBL2376032 | 0.82 | HPGD (0.75) | PKMHPGDKMT2AGLAPHGDH | |
| SCHEMBL15652033 | 0.82 | KMT2A (0.64) | PKMHPGDKMT2AGLAPHGDH | |
| SCHEMBL2377855 | 0.82 | KMT2A (0.64) | PKMHPGDKMT2AGLAPHGDH | |
| SCHEMBL9996865 | 0.80 | HSP90AA1 (0.63) | PKMHPGDKMT2AGLAPHGDH | |
| SCHEMBL13161947 | 0.80 | HPGD (1.00) | PKMHPGDKMT2APHGDHKDM4E | |
| SCHEMBL487574 | 0.80 | PKM (0.77) | PKMHPGDKMT2APHGDHKDM4E | |
| SCHEMBL17615025 | 0.79 | PKM (0.71) | PKMHPGDKMT2APHGDHKDM4E | |
| SCHEMBL2378109 | 0.79 | HPGD (0.67) | PKMHPGDKMT2AGLAPHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | PKM 1376/4885HPGD 1383/4885KMT2A 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.